FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2218678860> ?p ?o ?g. }

• W2218678860 endingPage "61" @default.
• W2218678860 startingPage "61" @default.
• W2218678860 abstract "Objective. To revise the South African Guideline for the Management of Chronic Obstructive Pulmonary Disease (COPD) based on emerging research that has informed updated recommendations. Key points. 1. Smoking is the major cause of COPD, but exposure to biomass fuels and tuberculosis are important additional factors. 2. Spirometry is essential for the diagnosis and staging of COPD. 3. COPD is either undiagnosed or diagnosed too late, so limiting the benefit of therapeutic interventions; performing spirometry in at-risk individuals will help to establish an early diagnosis. 4. Oral corticosteroids are no longer recommended for maintenance treatment of COPD. 5. A therapeutic trial of oral corticosteroids to distinguish corticosteroid responders from non-responders is no longer recommended. 6. Primary and secondary prevention are the most cost-effective strategies in COPD. Smoking cessation as well as avoidance of other forms of pollution can prevent disease in susceptible individuals and ameliorate progression. Bronchodilators are the mainstay of pharmacotherapy, relieving dyspnoea and improving quality of life. 7. Inhaled corticosteroids are recommended in patients with frequent exacerbations and have a synergistic effect with bronchodilators in improving lung function, quality of life and exacerbation frequency. 8. Acute exacerbations of COPD significantly affect morbidity, health care units and mortality. 9. Antibiotics are only indicated for purulent exacerbations of chronic bronchitis. 10. COPD patients should be encouraged to engage in an active lifestyle and participate in rehabilitation programmes. Options. Treatment recommendations are based on the following: annual updates of the Global Obstructive Lung Disease initiative (GOLD), that provide an evidence-based comprehensive review of management; independent evaluation of the level of evidence in support of some of the new treatment trends; and consideration of factors that influence COPD management in South Africa, including lung co-morbidity and drug availability and cost. Outcome. Holistic management utilising pharmacological and non-pharmacological options are put in perspective. Evidence. Working groups of clinicians and clinical researchers following detailed literature review, particularly of studies performed in South Africa, and the GOLD guidelines. Benefits, harms and costs. The guideline pays particular attention to cost-effectiveness in South Africa, and promotes the initial use of less costly options. It promotes smoking cessation and selection of treatment based on objective evidence of benefit. It also rejects a nihilistic or punitive approach, even in those who are unable to break the smoking addiction. Recommendations. These include primary and secondary prevention; early diagnosis, staging of severity, use of bronchodilators and other forms of treatment, rehabilitation, and treatment of complications. Advice is provided on the management of acute exacerbations and the approach to air travel, prescribing long-term oxygen and lung surgery including lung volume reduction surgery. Validation. The COPD Working Group comprised experienced pulmonologists representing all university departments in South Africa and some from private practice, and general practitioners. Most contributed to the development of the previous version of the South African guideline. Guideline sponsor. The meeting of the Working Group of the South African Thoracic Society was sponsored by an unrestricted educational grant from Boehringer Ingelheim and Glaxo-Smith-Kline." @default.
• W2218678860 created "2016-06-24" @default.
• W2218678860 creator A5001726265 @default.
• W2218678860 creator A5007314450 @default.
• W2218678860 creator A5032361558 @default.
• W2218678860 creator A5034288538 @default.
• W2218678860 creator A5037200463 @default.
• W2218678860 creator A5053699535 @default.
• W2218678860 creator A5056135996 @default.
• W2218678860 creator A5056603667 @default.
• W2218678860 creator A5061625886 @default.
• W2218678860 creator A5062455716 @default.
• W2218678860 creator A5064619973 @default.
• W2218678860 creator A5065782892 @default.
• W2218678860 creator A5073873019 @default.
• W2218678860 creator A5077087896 @default.
• W2218678860 creator A5077619974 @default.
• W2218678860 creator A5078615589 @default.
• W2218678860 creator A5079173990 @default.
• W2218678860 creator A5081458230 @default.
• W2218678860 creator A5087322384 @default.
• W2218678860 creator A5089044136 @default.
• W2218678860 date "2011-01-07" @default.
• W2218678860 modified "2023-10-17" @default.
• W2218678860 title "Guideline for the management of chronic obstructive pulmonary disease – 2011 update" @default.
• W2218678860 doi "https://doi.org/10.7196/samj.4490" @default.
• W2218678860 hasPublicationYear "2011" @default.
• W2218678860 type Work @default.
• W2218678860 sameAs 2218678860 @default.
• W2218678860 citedByCount "18" @default.
• W2218678860 countsByYear W22186788602015 @default.
• W2218678860 countsByYear W22186788602016 @default.
• W2218678860 countsByYear W22186788602018 @default.
• W2218678860 countsByYear W22186788602019 @default.
• W2218678860 countsByYear W22186788602021 @default.
• W2218678860 countsByYear W22186788602022 @default.
• W2218678860 countsByYear W22186788602023 @default.
• W2218678860 crossrefType "journal-article" @default.
• W2218678860 hasAuthorship W2218678860A5001726265 @default.
• W2218678860 hasAuthorship W2218678860A5007314450 @default.
• W2218678860 hasAuthorship W2218678860A5032361558 @default.
• W2218678860 hasAuthorship W2218678860A5034288538 @default.
• W2218678860 hasAuthorship W2218678860A5037200463 @default.
• W2218678860 hasAuthorship W2218678860A5053699535 @default.
• W2218678860 hasAuthorship W2218678860A5056135996 @default.
• W2218678860 hasAuthorship W2218678860A5056603667 @default.
• W2218678860 hasAuthorship W2218678860A5061625886 @default.
• W2218678860 hasAuthorship W2218678860A5062455716 @default.
• W2218678860 hasAuthorship W2218678860A5064619973 @default.
• W2218678860 hasAuthorship W2218678860A5065782892 @default.
• W2218678860 hasAuthorship W2218678860A5073873019 @default.
• W2218678860 hasAuthorship W2218678860A5077087896 @default.
• W2218678860 hasAuthorship W2218678860A5077619974 @default.
• W2218678860 hasAuthorship W2218678860A5078615589 @default.
• W2218678860 hasAuthorship W2218678860A5079173990 @default.
• W2218678860 hasAuthorship W2218678860A5081458230 @default.
• W2218678860 hasAuthorship W2218678860A5087322384 @default.
• W2218678860 hasAuthorship W2218678860A5089044136 @default.
• W2218678860 hasBestOaLocation W22186788601 @default.
• W2218678860 hasConcept C126322002 @default.
• W2218678860 hasConcept C142724271 @default.
• W2218678860 hasConcept C159110408 @default.
• W2218678860 hasConcept C177713679 @default.
• W2218678860 hasConcept C1862650 @default.
• W2218678860 hasConcept C27415008 @default.
• W2218678860 hasConcept C2776042228 @default.
• W2218678860 hasConcept C2776780178 @default.
• W2218678860 hasConcept C2777014857 @default.
• W2218678860 hasConcept C2777104659 @default.
• W2218678860 hasConcept C2777843972 @default.
• W2218678860 hasConcept C2779134260 @default.
• W2218678860 hasConcept C2779951463 @default.
• W2218678860 hasConcept C2780182762 @default.
• W2218678860 hasConcept C2780333948 @default.
• W2218678860 hasConcept C2992694001 @default.
• W2218678860 hasConcept C500440147 @default.
• W2218678860 hasConcept C71924100 @default.
• W2218678860 hasConceptScore W2218678860C126322002 @default.
• W2218678860 hasConceptScore W2218678860C142724271 @default.
• W2218678860 hasConceptScore W2218678860C159110408 @default.
• W2218678860 hasConceptScore W2218678860C177713679 @default.
• W2218678860 hasConceptScore W2218678860C1862650 @default.
• W2218678860 hasConceptScore W2218678860C27415008 @default.
• W2218678860 hasConceptScore W2218678860C2776042228 @default.
• W2218678860 hasConceptScore W2218678860C2776780178 @default.
• W2218678860 hasConceptScore W2218678860C2777014857 @default.
• W2218678860 hasConceptScore W2218678860C2777104659 @default.
• W2218678860 hasConceptScore W2218678860C2777843972 @default.
• W2218678860 hasConceptScore W2218678860C2779134260 @default.
• W2218678860 hasConceptScore W2218678860C2779951463 @default.
• W2218678860 hasConceptScore W2218678860C2780182762 @default.
• W2218678860 hasConceptScore W2218678860C2780333948 @default.
• W2218678860 hasConceptScore W2218678860C2992694001 @default.
• W2218678860 hasConceptScore W2218678860C500440147 @default.
• W2218678860 hasConceptScore W2218678860C71924100 @default.
• W2218678860 hasIssue "1" @default.
• W2218678860 hasLocation W22186788601 @default.
• W2218678860 hasOpenAccess W2218678860 @default.

• next